1h Free Analyst Time
The dry eye syndrome drugs market is forecasted to grow by USD 2.13 billion during 2023-2028, accelerating at a CAGR of 6.16% during the forecast period. The report on the dry eye syndrome drugs market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.Speak directly to the analyst to clarify any post sales queries you may have.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by growing geriatric population, growing healthcare expenditure, and changing lifestyles and rising cases of diseases contributing to dry eye syndrome.
The dry eye syndrome drugs market is segmented as below:
By Distribution Channel
- Retail pharmacies
- Hospital pharmacies
- Online pharmacies
By Product
- OTC drugs
- Prescription drugs
By Geography
- North America
- Europe
- Asia
- Rest of World (ROW)
The report on the dry eye syndrome drugs market covers the following areas:
- Dry eye syndrome drugs market sizing
- Dry eye syndrome drugs market forecast
- Dry eye syndrome drugs market industry analysis
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The report presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.
Table of Contents
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Distribution Channel
7 Market Segmentation by Product
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Opportunity/Restraints
11 Competitive Landscape
12 Competitive Analysis
13 Appendix
List of Exhibits
Executive Summary
The following companies are recognized as the key players in the global dry eye syndrome drugs market: Abbott Laboratories, AbbVie Inc., AFT Pharmaceuticals Ltd., Akorn Operating Co LLC, Bausch Health Companies Inc., F. Hoffmann La Roche Ltd., GlaxoSmithKline Plc, I MED Pharma Inc., Johnson and Johnson Services Inc., Laboratoires Thea, Mitotech SA, Novaliq GmbH, Novartis AG, Oasis Medical Inc., Otsuka Holdings Co. Ltd., Santen Pharmaceutical Co. Ltd., Sentiss Pharma Pvt. Ltd., Sun Pharmaceutical Industries Ltd., Viatris Inc., and Visufarma.Commenting on the report, an analyst from the research team said: "The latest trend gaining momentum in the market is advancements in drug delivery technologies."
According to the report, one of the major drivers for this market is the growing geriatric population.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Abbott Laboratories
- AbbVie Inc.
- AFT Pharmaceuticals Ltd.
- Akorn Operating Co LLC
- Bausch Health Companies Inc.
- F. Hoffmann La Roche Ltd.
- GlaxoSmithKline Plc
- I MED Pharma Inc.
- Johnson and Johnson Services Inc.
- Laboratoires Thea
- Mitotech SA
- Novaliq GmbH
- Novartis AG
- Oasis Medical Inc.
- Otsuka Holdings Co. Ltd.
- Santen Pharmaceutical Co. Ltd.
- Sentiss Pharma Pvt. Ltd.
- Sun Pharmaceutical Industries Ltd.
- Viatris Inc.
- Visufarma